Breaking Finance News

Citigroup Corp. upgraded Bayer (ETR:BAYN) to Buy in a statement released earlier today.

Just yesterday Bayer (ETR:BAYN) traded 7.14% lower at 91.44EUR. BAYN’s 50-day moving average is 0.04EUR and its two hundred day moving average is 0.03EUR. The last close is up 1.82% from the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. Volume of trade was was up over the average, with 10,000 shares of BAYN changing hands over the typical 211 shares..

Citigroup Corp. has upgraded Bayer(ETR:BAYN) to Buy in a report released 9/15/2016.

On 8/29/2016, Citigroup Corp. released a statement for Bayer(ETR:BAYN) upped the target price from 0.00EUR to 120.00EUR. At the time, this indicated a possible upside of 0.24%.

See Chart Below:

Bayer (ETR:BAYN)

Bayer has a 52 week low of 0.03EUR and a one-year high of 0.04EUR and has a total market value of 0.0 EUR.

About Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *